Document Detail


Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease.
MedLine Citation:
PMID:  11718676     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Arteriosclerosis is the major cause of death in patients with chronic renal failure. There is much interest in the lipid metabolism of patients treated with hemodialysis. METHODS: We analyzed low-density lipoproteins (LDL) and high-density lipoproteins (HDL) in chronic renal failure (CRF) patients according to patients on hemodialysis (HD), patients with diabetic nephropathy before initiation of dialysis (DN), and patients with chronic glomerulonephritis in the conservative stage (CGN); and compared the lipid metabolic abnormalities in patients on hemodialysis and those not yet on hemodialysis. We also analyzed the qualitative abnormalities of LDL and HDL and their relationship with the pathological stages. RESULTS: Electrophoretic patterns identified small LDL particles and small HDL particles in the three groups, and the degree of denaturation was more enhanced in CRF patients in the conservative stage than in HD patients. For LDL susceptibility to oxidation LDL (oxLDL) by addition of Cu(2+), the lag time was approximately 57 min in healthy controls and CGN patients, but was prolonged to approximately 75 min in HD and DN patients. For HDL susceptibility to oxidation HDL (oxHDL), HD, DN and CGN patients showed lag times shorter than those found in healthy control subjects. These results showed that LDL and HDL in the serum of CRF patients were in a state of enhanced susceptibility to oxidative modification. In Western blot analysis using anti-human-denatured LDL and anti-human-oxidized HDL monoclonal antibodies, bands of low molecular oxLDL at 150-197 kDa were detected in all CRF patients, with marked tailing in CGN patients. Similarly, bands of small oxHDL particles at 110 and 120 kDa were found in HD, DN and CGN patients. CONCLUSIONS: Oxidative modification of both LDL and HDL occurs in patients with advanced CRF resulting in small lipoproteins. Increased production of oxLDL and oxHDL is the main cause of lipid metabolic abnormality in CRF patients.
Authors:
M Tsumura; T Kinouchi; S Ono; T Nakajima; T Komoda
Related Documents :
21719716 - Aristolochic acid nephropathy: variation in presentation and prognosis.
22440606 - Treatment of progressive cerebral sinuses thrombosis with local thrombolysis.
16500696 - Sialic acid is an inflammation marker associated with a history of deep vein thrombosis.
22528966 - Cutaneous sympathetic dysfunction in patients with machado-joseph disease.
16183936 - Adverse cardiovascular and respiratory events during sedation of pediatric patients for...
16540876 - Differences in sitting postures are associated with nonspecific chronic low back pain d...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinica chimica acta; international journal of clinical chemistry     Volume:  314     ISSN:  0009-8981     ISO Abbreviation:  Clin. Chim. Acta     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-11-23     Completed Date:  2003-01-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1302422     Medline TA:  Clin Chim Acta     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  27-37     Citation Subset:  IM    
Affiliation:
R&D Center BML Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan. mac-g3@tk9.so-net.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blotting, Western
Cholesterol / blood
Diabetic Nephropathies / blood,  therapy
Electrophoresis, Polyacrylamide Gel
Female
Glomerulonephritis / blood,  therapy
Humans
Kidney Failure, Chronic / blood*,  therapy
Kidney Function Tests
Lipids / blood*
Lipoproteins / blood*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Male
Middle Aged
Oxidation-Reduction
Renal Dialysis
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Lipids; 0/Lipoproteins; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Triglycerides; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunosensors--principles and applications to clinical chemistry.
Next Document:  Differences in antioxidant status in skeletal muscle tissue in experimental diabetes.